Rocuronium-induced neuromuscular block is affected by chronic carbamazepine therapy

Anesthesiology

Volumn 90, Issue 1, 1999, Pages 109-112

  Spacek, Anna ^a,b   Neiger, Franz X ^a,b   Krenn, Claus G ^a,b   Hoerauf, Klaus ^a,b   Kress, Hans G ^a,b  

^a Dept Anesthesia Gen Intensive C ^*

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anticonvulsant; Drug interaction; Long term therapy; Muscle relaxant

Indexed keywords

ANDROSTANE DERIVATIVE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; NEUROMUSCULAR BLOCKING AGENT; ROCURONIUM;

ADULT; ANESTHETIC RECOVERY; ARTICLE; CLINICAL TRIAL; DRUG INTERACTION; ELECTROMYOGRAPHY; FEMALE; GENERAL ANESTHESIA; HUMAN; MALE;

ADULT; ANDROSTANOLS; ANESTHESIA RECOVERY PERIOD; ANESTHESIA, GENERAL; ANTICONVULSANTS; CARBAMAZEPINE; DRUG INTERACTIONS; ELECTROMYOGRAPHY; FEMALE; HUMANS; MALE; NEUROMUSCULAR NONDEPOLARIZING AGENTS;

EID: 0032622090     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-199901000-00016     Document Type: Article

References (23)

1. Ornstein E, Matteo RS, Schwartz AE, Silverberg PA, Young WL, Diaz J: The effect of phenytoin on the magnitude and duration of neuromuscular block following atracurium or vecuronium. ANESTHESIOLOGY 1987; 67:191-6
2. Whalley DG, Ebrahim ZY: Influence of carbamazepine on the dose-response relationship of vecuronium. Br J Anaesth 1994; 72: 125-6
3. Norman J: Resistance to vecuronium. Anaesthesia 1993; 48:1068-9
4. Liberman BA, Norman P, Hardy BG: Pancuronium-phenytoin interaction: A case of decreased duration of neuromuscular blockade. Int J Clin Pharmacol Ther Toxicol 1988; 26:371-4
5. Hickey DR, Sangwan S, Bevan JC: Phenytoin-induced resistance to pancuronium. Use of atracurium infusion in management of a neurosurgical patient. Anaesthesia 1988; 43:757-9
6. Roth S, Ebrahim ZY: Resistance to pancuronium in patients receiving carbamazepine. ANESTHESIOLOGY 1987; 66:691-3
7. Ornstein E, Matteo RS, Weinstein JA, Halevy JD, Young WL, Abou Donia MM: Accelerated recovery from doxacurium-induced neuromuscular blockade in patients receiving chronic anticonvulsant therapy. J Clin Anesth 1991; 3:108-11
8. Ornstein E, Matteo RS, Young WL, Diaz J: Resistance to metocurine-induced neuromuscular blockade in patients receiving phenytoin. ANESTHESIOLOGY 1985; 63:294-8
9. Kim CS, Arnold FJ, Itani MS, Martyn JAJ: Decreased sensitivity to metocurine during long-term phenytoin therapy may be attributable to protein binding and acetylcholine receptor changes. ANESTHESIOLOGY 1992; 77:500-6
10. Jellish WS, Modica PA, Tempelhoff R: Accelerated recovery from pipecuronium in patients treated with anticonvulsant therapy. J Clin Anesth 1993; 5:105-8
11. Spacek A, Neiger FX, Spiss CK, Kress HG: Chronic carbamazepine therapy does not influence the mivacurium-induced neuromuscular block. Br J Anaesth 1996; 77:500-2
12. Jellish WS, Thalji Z, Brundidge PK, Tempelhoff R: Recovery from mivacurium-induced neuromuscular blockade is not affected by anticonvulsant therapy. J Neurosurg Anesthesiol 1996; 8:4-8
13. Spacek A, Neiger FX, Spiss CK, Kress HG: Atracurium-induced neuromuscular block is not affected by chronic anticonvulsant therapy with carbamazepine. Acta Anaesthesiol Scand 1997; 41:1308-11
14. Tempelhoff R, Modica PA, Jellish WS, Spitznagel EL: Resistance to atracurium-induced neuromuscular blockade in patients with intractable seizure disorders treated with anticonvulsants. Anesth Analg 1990; 71:665-9
15. Szenohradszky J, Fisher DM, Segredo V, Caldwell JE, Bragg P, Sharma ML, Gruenke LD, Miller RD: Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. ANESTHESIOLOGY 1992; 77: 899-904
16. Magorian T, Wood P, Caldwell J, Fisher D, Segredo V, Szenohradszky J, Sharma M, Gruenke L, Miller R: The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. Anesth Analg 1995; 80:754-9
17. Szenohradszky J, Caldwell JE, Sharma ML, Gruenke LD, Miller RD: Interaction of rocuronium (ORG 9426) and phenytoin in a patient undergoing cadaver renal transplantation: A possible pharmacokinetic mechanism?. ANESTHESIOLOGY 1994; 80:1167-70
18. Baraka A, Idriss N: Resistance to rocuronium in an epileptic patient on long-term carbamazepine therapy - A case report. Middle East J Anesthesiol 1996; 13:561-4
19. Loan PB, Connolly FM, Mirakhur RK, Kumar N Farling P: Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs. Br J Anaesth 1997; 78:90-1
20. Viby-Mogensen J, Engbaek J, Eriksson LI, Gramstad L, Jensen E, Jensen FS, Koscielniak-Nielsen Z, Skovgaard LT, Østergaard D: Good clinical research practice (GCRP) in pharmacodynamic studies of neuromuscular blocking agents. Acta Anaesthesiol Scand 1996; 40:59-74
21. Anderson GD: A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998; 32:554-63
22. Savarese JJ, Ali HH, Basta SJ, Embree PB, Scott RP, Sunder N, Weakly JN, Wasila WB, El-Sayad HA: The clinical neuromuscular pharmacology of mivacurium chloride (BW B 1090U). A short-acting non-depolarizing ester neuromuscular blocking drug. ANESTHESIOLOGY 1988; 68:723-32
23. Alloul K, Whalley DG, Shutway F, Ebrahim Z, Varin F: Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ANESTHESIOLOGY 1996; 84:330-9